ADMA Biologics Announces Participation at Major Healthcare Event

ADMA Biologics Set to Present at Annual Healthcare Conference

ADMA Biologics, Inc. (Nasdaq: ADMA), an innovative biopharmaceutical company dedicated to the forefront of specialty biologics, is gearing up for a significant presentation at a prestigious healthcare conference. The firm's management announced that it will participate in the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco. The event, renowned for its focus on healthcare innovation, is scheduled for mid-January, where industry leaders gather to share insights and advancements.

Presentation Details

During this event, ADMA’s presentation is set for the morning of January 13, a date that aligns with the start of the conference. The timing, slated for 10:30 a.m. PT, positions ADMA to engage with an audience eager to learn about new developments in the biopharmaceutical sector, specifically regarding therapies aimed at immunodeficient patients.

Live Audio Webcast Available

For those unable to attend in person, a live audio webcast will be accessible through the investor section of the Company’s website. This allows interested parties to follow the presentation in real-time. Additionally, an archived version of the presentation will be made available shortly after the session concludes, ensuring that anyone who missed it can catch up on what was discussed.

About ADMA Biologics

ADMA Biologics is at the forefront of developing and marketing specialty biologics, focusing especially on treatments designed for patients with weakened immune systems. Their work is critical in the production of biopharmaceuticals that help these individuals not only protect against infections but also manage their conditions more effectively.

Product Portfolio

The company proudly manufactures several U.S. Food and Drug Administration (FDA)-approved plasma-derived biologics, which include BIVIGAM, ASCENIV, and NABI-HB. Each product plays a vital role in addressing the needs of those suffering from primary immunodeficiency and related complications. BIVIGAM serves as an immune globulin therapy essential for treating primary humoral immunodeficiency, while ASCENIV provides a more user-friendly formulation. NABI-HB, also essential, acts against the hepatitis B virus, offering enhanced immunity for patients who are at risk.

Operational Excellence in Boca Raton

ADMA’s manufacturing processes are rooted in a stringent quality assurance framework. Located in Boca Raton, Florida, their FDA-licensed facility is equipped to handle the complex processes necessary for transforming blood plasma into life-saving therapies. The company also engages in sourcing plasma through its ADMA BioCenters subsidiary, underscoring its commitment to maintaining a superior supply chain.

Company’s Vision and Impact

With a mission to address the specific healthcare needs of niche patient populations, ADMA aims to bring innovative solutions to the market. The company's focus extends beyond just treating diseases; they strive to improve the quality of life for individuals facing serious health challenges due to immune deficiencies.

Investor Relations Information

For investor inquiries or more details about the upcoming presentation and ADMA's activities, interested parties can reach out to Argot Partners. They provide further updates and information regarding the company’s operational strategies and future opportunities.

Frequently Asked Questions

What is the focus of ADMA Biologics?

ADMA Biologics specializes in manufacturing and marketing specialty biologics for immunodeficient patients and those at risk for infectious diseases.

When will ADMA's presentation take place?

ADMA will present on January 13, during the J.P. Morgan Healthcare Conference, at 10:30 a.m. PT.

How can I access the presentation?

A live audio webcast of the presentation will be available on the Company's website, with an archived version accessible afterwards.

What products does ADMA manufacture?

ADMA manufactures several FDA-approved biologics, including BIVIGAM, ASCENIV, and NABI-HB, targeting immune deficiencies and infectious disease prevention.

Where is ADMA Biologics' manufacturing facility located?

The company's manufacturing facility is situated in Boca Raton, Florida, ensuring high-quality production standards.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.